Pieter Sonneveld, MD, Erasmus MC Cancer Institute, discusses results from the PERSEUS clinical trial for patients with multiple myeloma.

 

 

Multiple myeloma is a bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.

The PERSEUS clinical trial is a phase 3, randomized, multicenter study comparing daratumumab, bortezomib, lenalidomide, and dexamethasone (D-VRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) in patients with previously untreated multiple myeloma.

The study enrolled 709 patients, 451 of which were tested for circulating tumor cells (CTCs). CTCs are a prognostic biomarker for risk stratification in patients with multiple myeloma. Prior to therapy, CTCs were found in 396 patients. Higher CTC was correlated with worse progression free survival (PFS). D-VRd treatment showed better PFS in both CTC-high and CTC-low patients than VRd treatment,

Minimal residual disease (MRD) negativity rates were higher in patients treated with D-VRd compared to VRd. Overall MRD-heg rates in CTC-high patients were 69% D-VRd versus 34% VRd and 47% D-VRd versus 22% VRd. Sustained MRD-neg rates in CTC-high patients were 50% D-VRd versus 16% VRd and 39% D-VRd versus 6% VRd.

For more information, click here.

To learn more about multiple myeloma and other rare cancers, visit https://checkrare.com/diseases/cancers/